Physician

Alana Margot Nevares, M.D

According to 2025 Medicare claims, Alana Nevares, M.D (NPI: 1386999597) practices rheumatology, with the plurality of this provider's patient population coming from Clinton, NY. This provider's primary affiliated billing organization is UNIVERSITY OF VERMONT MEDICAL CENTER INC (NPI: 1659309615; TIN: 030219309) and primary practice location at 05401-1473. Nevares is affiliated with the Adirondacks ACO, LLC (ACO ID: A2193) and Rochester Regional Health ACO, Inc. (ACO ID: A3476), participating under the MSSP model.

Nevares' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 244 traditional Medicare patients, billed 689 HCPCS/CPT codes, and received $46,926 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,517 prescription claims across 219 beneficiaries totaling $2,412,519 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 1 records totaling $1,400. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $17,692 and ending at $46,926. Concurrently, Part D prescription costs have risen steadily, from $5,684 to $2,412,519. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	145	257	$17,692
2019	220	600	$39,398
2020	238	585	$33,451
2021	238	490	$39,588
2022	226	407	$34,407
2023	163	264	$25,077
2024	244	689	$46,926

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	26	107	$5,684
2016	70	374	$39,082
2017	94	472	$133,715
2018	129	744	$402,983
2019	168	1,171	$1,070,422
2020	171	1,306	$1,294,260
2021	182	1,254	$1,354,540
2022	171	1,084	$1,254,403
2023	165	914	$1,263,400
2024	219	1,517	$2,412,519

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	49	49	$126
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	143	261	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	80	91	$71
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	16	18	$24
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	103	182	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	49	1,764	$524,708
Orencia Clickject	Abatacept	66	2,072	$397,001
Actemra Actpen	Tocilizumab	71	2,492	$250,483
Kevzara	Sarilumab	38	1,568	$233,825
Enbrel Sureclick	Etanercept	32	896	$218,391

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$1,400	Merck Sharp & Dohme LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alana Margot Nevares, M.D?

Tedicare shows public-source Medicare data for Alana Margot Nevares, M.D (NPI 1386999597), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alana Margot Nevares, M.D have ACO affiliation data?

Alana Margot Nevares, M.D is shown with ACO affiliation data for Adirondacks ACO, LLC (MSSP, ACO ID A2193) and Rochester Regional Health ACO, Inc. (MSSP, ACO ID A3476).

What billing organization is linked to Alana Margot Nevares, M.D?

Alana Margot Nevares, M.D is linked to UNIVERSITY OF VERMONT MEDICAL CENTER INC (billing NPI 1659309615) in the available physician profile data.

Does Alana Margot Nevares, M.D have Open Payments data?

Alana Margot Nevares, M.D has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.